+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

From
From
Pancreatic Endocrine Tumor - Pipeline Insight, 2025 - Product Thumbnail Image

Pancreatic Endocrine Tumor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
From
Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic M1 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic M1 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Laron Syndrome (LS) - Pipeline Insight, 2025 - Product Thumbnail Image

Laron Syndrome (LS) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Danon Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Danon Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Gaucher Disease Type 1 - Pipeline Insight, 2025 - Product Thumbnail Image

Gaucher Disease Type 1 - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Thyroid Eye Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Thyroid Eye Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hunter Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Hunter Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Congenital Hyperinsulinism - Pipeline Insight, 2025 - Product Thumbnail Image

Congenital Hyperinsulinism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Argininosuccinic Aciduria - Pipeline Insight, 2025 - Product Thumbnail Image

Argininosuccinic Aciduria - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Bardet-Biedl Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Bardet-Biedl Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Central Precocious Puberty - Pipeline Insight, 2025 - Product Thumbnail Image

Central Precocious Puberty - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Niemann Pick C Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Niemann Pick C Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Congenital Adrenal Hyperplasia- Pipeline Insight, 2025 - Product Thumbnail Image

Congenital Adrenal Hyperplasia- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more